Company intelligence / Profile preview
Vir Biotechnology
San Francisco, California, United Statesvir.bio ↗
- Ownership
- Public · VIR
- Employees
- ~750
- Development stage
- Commercial
01
Overview
Currently advancing Phase 3 trials for hepatitis delta with tobevibart + elebsiran, Phase 2 trials for hepatitis B, and multiple Phase 1 trials for solid tumors. Previously developed sotrovimab (Xevudy) for COVID-19 which received Emergency Use Authorization in 2021.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodiesT cell-based viral vectorsRNA interference (RNAi)Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
27 assets26 more assets in the full pipeline.
03
Partnerships
GlaxoSmithKline (GSK)AlnylamBill & Melinda Gates Foundation
04
Financials
- Market cap
- $1.9B
- Total revenue
- $68.6M
- Enterprise value
- $1.5B
Beyond the preview
Go deeper on Vir Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vir Biotechnology.